Boston, Massachusetts


This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a day in subjects with Diabetic Macular Edema and Age-Related Macular Degeneration.


Inclusion Criteria: - General: 1. Adults aged ≥18 and ≤ 80 years 2. Women of childbearing potential must have a negative urine pregnancy test at Baseline and agree to use a highly effective method of contraception throughout the study and 60 days after the last dose of study drug. - DME Treatment Group: 1. Central subfield thickness (CST) ≥325 microns as measured by spectral domain optical coherence tomography (SD-OCT) at Screening and Baseline Visits 2. BCVA (ETDRS) no better than 20/25 in the study eye 3. BCVA (ETDRS) no worse than 20/640 in either eye - AMD Treatment Group: 1. Non-exudative, intermediate age-related macular degeneration defined as an eye(s) having extensive intermediate drusen (10 or more drusen 63μm - 124μm) or large drusen (1 or more ≥125 μm) with no evidence of advanced AMD (i.e., no choroidal neovascularization or macular atrophy) 2. BCVA (ETDRS) no worse than 20/400 in either eye Exclusion Criteria: - General: 1. Inability to self-administer eye drops 2. Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve (for example deferoxamine, chloroquine/hydroxychloroquine [Plaquenil], tamoxifen, phenothiazines and ethambutol) 3. Any medical condition that, in the opinion of the investigator, would preclude safe participation in the study or completion of all study requirements and examinations 4. Have a glycosylated hemoglobin (HbA1c) ≥ 12% - Ocular Conditions: 1. Any ocular condition in the study eye that in the opinion of the investigator would prevent improvement in visual acuity or successful completion of any study examination 2. Ocular hypertension or glaucoma, dry eye, and any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops - Other protocol-defined inclusion/exclusion criteria may apply



Primary Contact:

Stealth Peptides Inc.
Phone: (617) 600-6888

Backup Contact:


Location Contact:

Boston, Massachusetts
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.